Login / Signup

Microbiome-Friend or Foe of Pancreatic Cancer?

Jaroslaw DanilukUrszula DanilukPawel RogalskiAndrzej DabrowskiAgnieszka Swidnicka-Siergiejko
Published in: Journal of clinical medicine (2021)
Pancreatic ductal adenocarcinoma is one of the deadliest human neoplasms. Despite the development of new surgical and adjuvant therapies, the prognosis remains very poor, with the overall survival rate not exceeding 9%. There is now increasing evidence that the human microbiome, which is involved in many physiological functions, including the regulation of metabolic processes and the modulation of the immune system, is possibly linked to pancreatic oncogenesis. However, the exact mechanisms of action are poorly understood. Our review summarizes the current understanding of how the microbiome affects pancreatic cancer development and progression. We discuss potential pathways of microbe translocation to the pancreas, as well as the mechanism of their action. We describe the role of the microbiome as a potential marker of pancreatic cancer diagnosis, progression, and survival. Finally, we discuss the possibilities of modifying the microbiome to improve treatment effectiveness for this deadly disease.
Keyphrases
  • endothelial cells
  • randomized controlled trial
  • induced pluripotent stem cells
  • systematic review
  • pluripotent stem cells
  • combination therapy